Parametric Portfolio Associates LLC lifted its stake in Enzo Biochem, Inc. (NYSE:ENZ) by 136.7% in the second quarter, HoldingsChannel.com reports. The firm owned 72,653 shares of the medical research company’s stock after purchasing an additional 41,963 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Enzo Biochem were worth $245,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of ENZ. Renaissance Technologies LLC increased its holdings in shares of Enzo Biochem by 2.1% in the second quarter. Renaissance Technologies LLC now owns 3,251,033 shares of the medical research company’s stock valued at $10,956,000 after purchasing an additional 65,804 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Enzo Biochem by 11.3% in the second quarter. Bank of New York Mellon Corp now owns 249,095 shares of the medical research company’s stock valued at $839,000 after purchasing an additional 25,203 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Enzo Biochem by 9.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 254,331 shares of the medical research company’s stock valued at $858,000 after purchasing an additional 22,156 shares in the last quarter. Cutter & CO Brokerage Inc. acquired a new stake in shares of Enzo Biochem in the second quarter valued at approximately $63,000. Finally, SG Americas Securities LLC increased its holdings in shares of Enzo Biochem by 130.9% in the second quarter. SG Americas Securities LLC now owns 30,693 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 17,399 shares in the last quarter. 68.28% of the stock is owned by institutional investors and hedge funds.
ENZ opened at $3.23 on Friday. The company has a fifty day moving average price of $3.47 and a two-hundred day moving average price of $3.52. The company has a quick ratio of 5.12, a current ratio of 5.09 and a debt-to-equity ratio of 0.05. Enzo Biochem, Inc. has a 52 week low of $2.32 and a 52 week high of $4.46.
Enzo Biochem (NYSE:ENZ) last released its earnings results on Tuesday, October 15th. The medical research company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. Enzo Biochem had a net margin of 3.07% and a negative return on equity of 33.03%. The firm had revenue of $20.92 million during the quarter.
In other Enzo Biochem news, major shareholder Discovery Fund Lp Harbert bought 32,500 shares of the stock in a transaction on Tuesday, August 20th. The stock was purchased at an average price of $3.07 per share, with a total value of $99,775.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Harbert Management Corp bought 22,800 shares of the stock in a transaction on Friday, August 16th. The shares were acquired at an average cost of $3.06 per share, with a total value of $69,768.00. The disclosure for this purchase can be found here. Insiders have acquired a total of 64,944 shares of company stock valued at $204,647 in the last ninety days. Company insiders own 9.40% of the company’s stock.
Separately, TheStreet raised shares of Enzo Biochem from a “d” rating to a “c-” rating in a report on Tuesday, July 2nd.
Enzo Biochem Profile
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics.
Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.